Abstract
The human disease tuberculosis (TB) is the leading cause of death from a single infectious agent. A quarter of the world’s population is estimated to be latently infected. Drug development and screening is slow and costly. We have developed a physiologically relevant assay to screen drugs against TB when inside immune cells. This chapter will describe a newly developed preclinical drug screening assay for TB, using high content imaging and pharmacokinetic/pharmacodynamic modeling.
| Original language | English |
|---|---|
| Title of host publication | Methods in Molecular Biology |
| Publisher | Springer |
| Pages | 393-408 |
| Number of pages | 16 |
| ISBN (Electronic) | 1940-6029 |
| ISBN (Print) | 1064-3745 |
| DOIs | |
| Publication status | E-pub ahead of print - 24 Jun 2021 |
Publication series
| Name | Methods in Molecular Biology |
|---|---|
| Publisher | Humana Press Inc. |
| ISSN (Print) | 1064-3745 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antibiotics
- Drug screening
- Mycobacteria
- Pharmacokinetic and pharmacodynamic drug Modeling
- Tuberculosis
Fingerprint
Dive into the research topics of 'Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose–Response Relationship Using Intracellular Pharmacodynamic Modeling (PDi)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver